ICE-HBV & partners are organizing a session at the Global Fund’s replenishment conference in Lyon. Please contact email@example.com to register (free).
The goal of this session is to underscore the potential public health impact of expanding viral hepatitis elimination programming, including through strategic integration with existing efforts to improve HIV care and prevention outcomes. The full programme is available here.
ICE-HBV is organizing an HBV Cure 101 session at COLDA to enhance awareness about HBV Cure research in Africa. Anna Kramvis will represent ICE-HBV and share an update about the latest sience before discussing cure prospects with Manal El-Sayed (Clinician) and Kenneth Kabagambe (Community).
The 6th edition of the International HBV Cure Workshop 2019, which will take place on 6 November 2019 in Toronto, Canada. Since 2014, the HBV Cure Workshop is a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure. This meeting will bring together the world’s leading basic, translational and clinical experts to share and discuss the latest research outcomes and challenges.
Details can be found here.
ICE-HBV in-vivo models project group is holding a workshop immediately before the International HBV Meeting. If you wish to attend, you can register here.
The objectives are:
1. Evaluation of current available models and their respective usage in various basic studies and drug assessment. Each presenter to perform a SWAT/comparative analysis of the models they present.
2. Discussion on features needed for an ideal model for assessing agent(s) with curative potential
3. Gap analysis and roadmap for developing models amenable for HBV infection and disease development. The roadmap will be published as review article/opinion piece.
The full programme can be found below and printed here.
|ICE-HBV welcome and introductions
||T. Jake Liang
|What we learned about HBV pathogenesis and immune intervention in chimpanzees, woodchucks and immunocompetent transgenic mice
||Luca G. Guidotti
|Comparison of the Adeno-HBV, the AAV-HBV and the HBVtg mouse models
|Hydrodynamic injection mouse model
|Mouse models based on stem cell derived hepatocytes/FAH
|Human liver chimeric mice and their application for drug assessment
|Liver and immune system humanized mouse models to study pathophysiology and therapeutics.
||Hélène Strick Marchand
|11:20 – 11:55
|Mouse with humanized NTCP
|Towards a mouse model susceptible to HBV infection – overcoming the barrier to cccDNA formation.
|Macaque with human NTCP for HBV infection
|Industry perspective in most wanted features for HBV animal models
|Panel Discussion (facilitation by T. Jake Liang)
||Hélène Strick Marchand & Wenhui Li
In 2019, the IAS Towards an HIV Cure initiative, in collaboration with the International Coalition to Eliminate Hepatitis B (ICE-HBV), will organize a 1.5 day HIV & HBV Cure Forum on 20 & 21 July 2019, immediately preceding the 10th IAS Conference on HIV Science (IAS 2019).
Abstract are accepted until 22 January 2019. Use the IAS 2019 system to submit.
Learn more about the Forum here.
The International HBV Meeting is coming to Melbourne, the home-base of ICE-HBV. We will take this opportunity to co-organize a public forum, stay tuned! http://www.hbvmeeting.org/
The preliminary programme will be available shortly.
The purpose of this workshop is to bring together the academic, regulatory and pharmaceutical (diagnostic and therapeutic) communities to discuss therapeutic endpoints, trial designs, appropriate patient populations and safety concerns with regards to novel therapeutic approaches aimed to achieve HBV cure. This meeting will bring all the stakeholders together to discuss definitions of HBV cure, likelihood of HBV cure with currently approved therapies, preclinical and clinical data on novel antiviral and immune modulatory therapies, appropriate designs and endpoints for trials to evaluate therapies aimed at HBV and HDV cure, and strategies to efficiently and safely evaluate combination therapies. These discussions will provide guidance regarding potential pathways leading to regulatory approval of therapies that will result in high rates of HBV cure in individuals with chronic hepatitis B and chronic hepatitis D.
Dr Mehlika Toy, Ph.D.,research scientist at Stanford University and ICE-HBV member presents the first results from her HBV cure modelling study in Australia.